New Advances in Molecular Research in Leukemia
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 90
Special Issue Editors
Interests: Immunotherapy for hematological cancers; hematopoietic stem cell transplantation; laboratory hematology; the immunological effects of phytochemicals; transfusion medicine; bone marrow failure
Special Issues, Collections and Topics in MDPI journals
Interests: hematology and oncology; microbe-induced carcinogenesis; cancer drug discovery; parasitic infections; opportunistic microorganisms; immunology; microbiota; infectious diseases; artificial intelligence and medical sciences
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue entitled “New Advances on Molecular Research in Leukemia.”
According to recent reports, the incident cases of hematologic malignancies have been increasing worldwide since 1990, reaching nearly 1.35 million in 2019, and while the age-standardized death rate (ASDR) for almost all types of hematologic malignancies is declining, leukemia remains the hematologic malignancy with the highest incidence and mortality, with an ASDR of 4.26 per 100,000 people in 2019. Among the highly heterogenous leukemia types, from 1990 to 2019, chronic myeloid leukemia (CML) was the type of leukemia with a decreased age-standardized incidence rate (AISR), while acute myeloid leukemia (AML) was the type of leukemia with an increased ADSR. Nevertheless, our understanding of the biology of leukemias is progressing rapidly, and novel therapeutic agents have been approved for various indications in leukemia. Moreover, accelerated advances in personalized medicine and genomics have contributed significantly to improving the diagnosis, classification, risk stratification, and management of leukemias. Furthermore, the introduction of new classes of targeted therapies and refinements in measurable residual disease (MRD) testing has changed the standard of care for patients with these malignancies. This Special Issue aims to explore recent advances in all types of leukemias, including AML, acute lymphoblastic leukemia (ALL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), myelodysplastic neoplasm (MDS), myeloproliferative neoplasm (MPN), CML, and chronic lymphocytic leukemia (CLL).
We welcome the submission of original research articles, reviews, and commentaries. Research areas may include (but are not limited to) the following: leukemogenesis, disease classification, prognostic factors, measurable residual disease (MRD), biomarkers of treatment response, targeted therapies, experimental agents, and clinical trials.
Prof. Dr. Akiyoshi Takami
Dr. Jorge Luis Espinoza
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute lymphoblastic leukemia (ALL)
- chronic lymphocytic leukemia (CLL)
- acute myelogenous leukemia (AML)
- chronic myelogenous leukemia (CML)
- hairy cell leukemia (HCL)
- T-cell prolymphocytic leukemia (T-PLL)
- large granular lymphocytic leukemia
- measurable residual disease (MRD)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
